Cutler Group’s Capricor Therapeutics CAPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-3,400
Closed -$2K 3869
2022
Q4
$2K Sell
3,400
-800
-19% -$3.82K ﹤0.01% 3640
2022
Q3
$5K Hold
4,200
﹤0.01% 3619
2022
Q2
$10K Hold
4,200
﹤0.01% 3172
2022
Q1
$9K Sell
4,200
-5,500
-57% -$21.7K ﹤0.01% 3677
2021
Q4
$15K Buy
9,700
+3,300
+52% +$11.6K ﹤0.01% 3337
2021
Q3
$13K Sell
6,400
-3,300
-34% -$15K ﹤0.01% 3692
2021
Q2
$13K Buy
9,700
+1,600
+20% +$6.78K ﹤0.01% 3667
2021
Q1
$12K Buy
+8,100
New +$46.7K ﹤0.01% 3629
2020
Q4
Sell
-6,100
Closed -$4K 4837
2020
Q3
$4K Buy
+6,100
New +$35.6K ﹤0.01% 3618

Other funds holding CAPR

Cutler Group's CAPR Position: Q4 2023 in Review

Cutler Group sold out of Capricor Therapeutics (CAPR) in Q4 2023, closing a stake of 1,000 shares — an estimated $3K sold.

Cutler Group first reported a position in CAPR in Q3 2020 and held it in 13 quarters. The position peaked at $57K in Q3 2021. 37 funds tracked by Wall St. Rank hold CAPR as of Q4 2023.

  • Cutler Group reported no remaining Capricor Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Cutler Group sold 1,000 Capricor Therapeutics shares in Q4 2023, an estimated $3K.
  • Cutler Group first reported a position in Capricor Therapeutics in Q3 2020 and held it in 13 quarters.
  • Cutler Group's Capricor Therapeutics position peaked at $57K in Q3 2021.
  • 37 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.